Barron's
http://online.barrons.com/public/mainBarron's Magazine is a weekly financial newspaper that covers US financial information, market developments, and relevant statistics. Each issue provides a summary of the previous week's market activity, news reports, and an outlook on the week to come. The paper has been published since 1921 by Dow Jones & Company, the publisher of The Wall Street Journal. The paper is named after Clarence W. Barron who is considered the founder of financial journalism.
-
EarthLink (ELNK) Remains Significantly Undervalued Given Potential - Barron's
-
Barron's Gives Top 10 Picks for 2012, But Don't Rush In Yet...
-
Cablevision (CVC) in Strong Position Based on Valuation, M&A Potential - Barron's
-
Bull Appears on Sprint (S); Says iPhone Numbers Unbelievable
-
Sprint (S) is in Prickly Situation... Will Investors Hold on For 4G? - Barron's
-
Motorola Mobility (MMI) Ripe for Picking Ahead of Summer Launches - Barron's
-
Pre-Open Movers 3/21 (OXPS) (TIF) (T) Higher; (XNPT) (S) (CCI) Lower
-
Notable 52-Week Highs and Lows of the Day 01/18: ARIA, VOD, MYL, SSN High; EAR, AB Low
-
Vodafone (VOD) Better Play on CDMA iPhone (AAPL) than Verizon (VZ)
-
Sierra Wireless (SWIR) Shares Up 8% on Positive Article - Barron's
-
Dippin' Chips: Analog Devices (ADI) Should See Boost in Q211 - Barron's
-
Fontier Communications (FTR) Provides Investors with a Solid 'Triple Play' - Barron's
-
BCE (BCE) Has Room to Grow in the Great White North - Barron's (T, VZ, RCI, TU)
-
Palm's (PALM) Drooping Pre/Pixi Sales, Takeover Potential Not Enough Reason to Keep in Your Portfolio - Barron's
-
Time Warner (TWC) is Upgrading Earnings Picture to High-Def - Barron's
-
3Par (PAR) May Be a Hot Takeover Target in the Near Term - Barron's (VZ, CS, PCLN, More)
-
AT&T Aims to Speed Dial Earnings for Investors - Barron's (T, AAPL, VZ, CMCSA, TWC)
-
Barron's Midyear Roundtable Results (Pimco's Bill Gross)
-
Year-Long Decline in Ciena (CIEN) Creates Buying Opportunity -Barron's
-
Pre-Open Movers 7/28: Amgen (AMGN) Up On Positive osteoporosis Trial; Vanda (VNDA) Sinks On FDA 'Not Approvable"

